Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ifosfamide in urologic cancer.

F Boccardo1, P Guglielmini

  • 1Academic Department of Medical Oncology, Medical Oncology B, National Cancer Research Institute and University of Genoa, Genoa, Italy. francesco.boccardo@istge.it

Oncology
|October 31, 2003
PubMed
Summary

Ifosfamide shows significant therapeutic activity in pediatric nephroblastoma and urothelial tract malignancies, offering a key treatment option. Its efficacy in other urologic tumors like renal cancer and prostate cancer is modest, with limited data for penile cancer.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Case Series on Combining Modified Mediterranean Diet and Ketogenic Diet in a "Sandwich" Approach for Patients with Lipedema and Comorbidities.

Lymphology·2025
Same author

Genetic Variants in the Transcription Factor Network: The Impact of <i>FOXC1, NOTCH1, RORC, FOXC</i>2 and <i>SOX18</i> in Primary Lymphedema.

Lymphology·2025
Same author

Genetic Variants in <i>LZTR1, MAP2K1</i> and <i>RAF1</i>: Insights into the Role of RAS-MAPK Pathway in Primary Lymphedema.

Lymphology·2025
Same author

Genetic Variants in Genes Correlated to the PI3K/AKT Pathway: The Role of <i>ARAP3, CDH5, KIF11</i> and <i>RELN</i> in Primary Lymphedema.

Lymphology·2024
Same author

Fungal Planet description sheets: 1614-1696.

Fungal systematics and evolution·2024
Same author

Fungal Planet description sheets: 1383-1435.

Persoonia·2024

Area of Science:

  • Oncology
  • Urology
  • Pharmacology

Background:

  • Ifosfamide is an alkylating agent used in cancer chemotherapy.
  • Its role in various urologic malignancies requires comprehensive review.

Purpose of the Study:

  • To review the therapeutic activity of ifosfamide in different urologic tumors.
  • To assess its efficacy as a treatment option for various cancers of the urinary tract.

Main Methods:

  • Literature review of studies evaluating ifosfamide in urologic cancers.
  • Analysis of treatment outcomes and toxicity profiles.

Main Results:

  • Definite activity observed in nephroblastoma (pediatric and adult) and urothelial tract malignancies, especially in relapsed or refractory cases.

Related Experiment Videos

  • Promising results in chemo-naïve urothelial cancer patients when combined with taxanes or gemcitabine, albeit with significant toxicity.
  • Modest activity noted in renal cancer and hormone-refractory prostate cancer.
  • No available data for penile carcinoma.

    • Conclusions:

    • Ifosfamide is a valuable therapeutic option for specific urologic tumors, particularly nephroblastoma and urothelial malignancies.
    • Its use in other urologic cancers is limited by modest efficacy and toxicity concerns.
    • Further research is needed for penile carcinoma and optimizing combination therapies.